CLIN
Cynthia Brown, MD
Pulmonary & Critical Care Medicine
Indiana University School of Medicine
Gregory Sawicki, MD, MPH
Cystic Fibrosis Center
Boston Children's Hospital
Since the approval of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in 2019, people living with CF eligible for this medication have experienced substantial gains in health and quality of life. This symposium will focus on the real-world outcomes related to use of ELX/TEZ/IVA post-approval and will include studies about withdrawing chronic daily therapies.
Speaker: George M. Solomon, M.D. – University of Alabama at Birmingham
Speaker: David P. Nichols, MD – Univ. of Washington
Speaker: Gwyneth Davies, MBChB, PhD – UCL Great Ormond Street Institute of Child Health
Speaker: Clement Ren, MD, MBA – Children's Hospital of Philadelphia